Sarah Alami

Dr. Sarah Alami

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
SASarah Alami
Sarah Alami
LCLaurène COUROUVE
Laurène COUROUVE
GLGuila Lancman
Guila Lancman
PGPierrette GOMIS
Pierrette GOMIS
GAGisele Al-Hamoud
Gisele Al-Hamoud
IAIsabelle APHP
Isabelle APHP
Remote patient monitoring (RPM) for the management of patients with chronic heart failure (CHF) has been widely studied from clinical and health-economic points of view. In contrast, data on the organisational impact of this type of RPM are scarce. The objective of the present study of cardiology departments (CDs) in France was to describe the organisational impact of the Chronic Care ConnectTM (CCCTM) RPM system for CHF. An organisational impact map for health technology assessment was used to identify and define the criteria evaluated in the present survey, including the care process, equipment, infrastructure, training, skill transfers, and the stakeholders’ abilities to implement the care process. In April 2021, an online questionnaire was sent to 31 French CDs that were using CCCTM for CHF management: 29 (94%) completed the questionnaire. The survey results showed that CDs progressively modified their organisational structures upon or shortly after the implementation of the RPM device. Twenty-four departments (83%) had created a dedicated team, sixteen (55%) had provided dedicated outpatient consultations for patients with an emergency alert, and twenty-five (86%) admitted patients directly (i.e., avoiding the need to attend the emergency department). The present survey is the first to have assessed the organisational impact of the implementation of the CCCTM RPM device for CHF management. The results highlighted the variety of organisational structures, which tended to structure with the use of the device.

7 March 2024 in European Journal of Heart Failure
Verified
Journal Article
Open access
FRFrançois Roubille
François Roubille
GMGrégoire Mercier
Grégoire Mercier
GLGuila Lancman
Guila Lancman
HPHélène Pasche
Hélène Pasche
SASarah Alami
Sarah Alami
IAIsabelle APHP
Isabelle APHP
Aims: Evaluating the benefit of telemonitoring in heart failure (HF) management in real-world settings is crucial for optimizing the healthcare pathway. The aim of this study was to assess the association between a 6-month application of the telemonitoring solution Chronic Care Connect™ (CCC) and mortality, HF hospitalizations, and associated costs compared with standard of care (SOC) in patients with a diagnosis of HF. Methods and results: From February 2018 to March 2020, a retrospective cohort study was conducted using the largest healthcare insurance system claims database in France (Système National des Données de Santé) linked to the CCC telemonitoring database of adult patients with an ICD-10-coded diagnosis of HF. Patients from the telemonitoring group were matched with up to two patients from the SOC group based on their high-dimensional propensity score, without replacement, using the nearest-neighbour method. A total of 1358 telemonitored patients were matched to 2456 SOC patients. The cohorts consisted of high-risk patients with median times from last HF hospitalization to index date of 17.0 (interquartile range: 7.0–66.0) days for the telemonitoring group and 27.0 (15.0–70.0) days for the SOC group. After 6 months, telemonitoring was associated with mortality risk reduction (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.56–0.89), a higher risk of first HF hospitalization (HR 1.81, 95% CI 1.55–2.13), and higher HF healthcare costs (relative cost 1.38, 95% CI 1.26–1.51). Compared with the SOC group, the telemonitoring group experienced a shorter average length of overnight HF hospitalization and fewer emergency visits preceding HF hospitalizations. Conclusion: The results of this nationwide cohort study highlight a valuable role for telemonitoring solutions such as CCC in the management of high-risk HF patients. However, for telemonitoring solutions based on weight and symptoms, consideration should be given to implement additional methods of assessment to recognize imminent worsening of HF, such as impedance changes, as a way to reduce mortality risk and the need for HF hospitalizations. Further studies are warranted to refine selection of patients who could benefit from a telemonitoring system and to confirm long-term benefits in high-risk and stable HF patients.

7 August 2023 in JMIR Formative Research
Verified
Journal Article
Open access
HMHemant Makan
Hemant Makan
LMLindie Makan
Lindie Makan
JLJacqueline Lubbe
Jacqueline Lubbe
SASarah Alami
Sarah Alami
GLGuila Lancman
Guila Lancman
AKAdri Kok
Adri Kok
Background: In South Africa, diabetes prevalence is expected to reach 5.4 million by 2030. In South Africa, diabetes-related complications severely impact not only patient health and quality of life but also the economy. Objective: The Diabetes Nurse Educator (DNE) study assessed the benefit of adding the MyDiaCare program to standard of care for managing patients with type 1 and type 2 diabetes in South Africa. An economic study was also performed to estimate the budget impact of adding MyDiaCare to standard of care for patients with type 2 diabetes older than 19 years treated in the South African private health care sector. Methods: The real-world DNE study was designed as an observational, retrospective, multicenter, single-group study. Eligible patients were older than 18 years and had at least 6 months of participation in the MyDiaCare program. The MyDiaCare program combines a patient mobile app and a health care professional platform with face-to-face visits with a DNE. The benefit of MyDiaCare was assessed by the changes in glycated hemoglobin (HbA1c) levels, the proportion of patients achieving clinical and biological targets, adherence to care plans, and satisfaction after 6 months of participating in the MyDiaCare program. A budget impact model was performed using data from the DNE study and another South African cohort of the DISCOVERY study to estimate the economic impact of MyDiaCare. Results: Between November 25, 2019, and June 30, 2020, a total of 117 patients (8 with type 1 diabetes and 109 with type 2 diabetes) were enrolled in 2 centers. After 6 months of MyDiaCare, a clinically relevant decrease in mean HbA1c levels of 0.6% from 7.8% to 7.2% was observed. Furthermore, 54% (43/79) of patients reached or maintained their HbA1c targets at 6 months. Most patients achieved their targets for blood pressure (53/79, 67% for systolic and 70/79, 89% for diastolic blood pressure) and lipid parameters (49/71, 69% for low-density-lipoprotein [LDL] cholesterol, 41/71, 58% for high-density-lipoprotein [HDL] cholesterol, and 59/71, 83% for total cholesterol), but fewer patients achieved their targets for triglycerides (32/70, 46%), waist circumference (12/68, 18%), and body weight (13/76, 17%). The mean overall adherence to the MyDiaCare care plan was 93%. Most patients (87/117, 74%) were satisfied with the MyDiaCare program. The net budget impact per patient with type 2 diabetes, older than 19 years, treated in the private sector using MyDiaCare was estimated to be approximately South African Rands (ZAR) 71,023 (US $4089) during the first year of introducing MyDiaCare. Conclusions: The results of using MyDiaCare program, which combines digital tools for patients and health care professionals with DNE support, suggest that it may be a clinically effective and cost-saving solution for diabetes management in the South African private health care sector.

31 January 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
SASarah Alami
Sarah Alami
MSManuella Schaller
Manuella Schaller
SBSylvie Blais
Sylvie Blais
HTHenry Taupin
Henry Taupin
MGMarta Hernández González
Marta Hernández González
JTJoëlle Texereau
Joëlle Texereau
Background: Adherence and persistence to positive airway pressure (PAP) therapy are key factors for positive health outcomes. Home support providers participate in the home implementation and follow-up of PAP therapy for patients with obstructive sleep apnea (OSA). In Europe, home support provider service levels are country (or area) specific, resulting in differences in content and frequency of patient interactions. However, no robust evaluation of the impact of these differences on clinical and patient outcomes has been performed. Objective: The AWAIR study aims to evaluate and compare the impact of different home support provider service levels on PAP adherence and persistence in 4 European countries. Methods: This real-world, ambispective, cohort study—conducted in France, Belgium, Spain, and Portugal—will recruit adults with OSA who started PAP therapy between 2019 and 2023 and were followed by an Air Liquide Healthcare home support provider. Given the large number of eligible participants (around 150,000), the study will use a decentralized and digital approach. A patient video will present the study objectives and the participation process. A secure electronic solution will be used to manage patient information and consent, as well as to administer a web-based questionnaire. Retrospective data, collected during routine patient follow-up by home support providers, include the level of service and device data, notably PAP use. Prospective data collected using an electronic patient-reported outcome tool include health status, OSA-related factors, patient-reported outcomes including quality of life and symptoms, OSA and PAP literacy, patient-reported experience, and satisfaction with PAP therapy and service. Hierarchical models, adjusted for preidentified confounding factors, will be used to assess the net effect of home support provider services on PAP adherence and persistence while minimizing real-world study biases and considering the influence of country-level contextual factors. We hypothesize that higher levels of home support provider services will be positively associated with adherence and persistence to PAP therapy. Results: As of December 2024, the study has received approval in France, Portugal, and 2 regions of Spain. The study began enrollment in France in October 2024. Results are expected in the second quarter of 2025. Conclusions: The AWAIR study has a unique design, leveraging an unprecedented number of eligible participants, decentralized technologies, and a real-world comparative methodology across multiple countries. This approach will highlight intercountry differences in terms of patient characteristics, PAP adherence, and persistence, as well as patient-reported outcomes, patient-reported experiences, and satisfaction with the home service provider. By assessing the added value of home support provider services, the results will support best practices for patient management and for decision-making by payers and authorities. International Registered Report Identifier (IRRID): PRR1-10.2196/65840

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
SASarah Alami
Sarah Alami
MLMarie Lambert
Marie Lambert
DRDavid Rudilla
David Rudilla
ILImbault Lea
Imbault Lea
RARoman Ana
Roman Ana
LJLeonardi Jennifer
Leonardi Jennifer
Introduction: Respiratory chronic conditions represent a high burden for healthcare systems. To address these, the Value-Based Healthcare (VBHC) approach ensures better correlation between patient outcomes and costs, which homecare providers can actively support by: personalizing patient support collecting patient outcomes, and adapting support over time based on patient needs Different studies have positively demonstrated the value of this support. However, scaling up live implementation remains a challenge as it requires significant human and technical resources. Method: This evaluation explores homecare provider implementation of Positive Airway Pressure (PAP) and non-invasive ventilation (NIV) therapies with personalization through outcomes collection. This was executed in two levels: Level 1 ‘Device-Centric’: reactive personalized support based on compliance and/or AHI, and/or leaks. Level 2 ‘Outcome-Centric’: predictive personalized support based on clinical outcomes (CROM) and patient reported outcomes (PROM) (table 1). Literature review and patient surveys on outcomes that matter for them were studied and chosen with clinicians. According to patient profiles, personalized care plans are defined: frequency of interactions, educational support, and coordination with healthcare professionals. Results: The number of patients under level 1 in PAP and NIV in 20 countries is already significant, respectively 66% and 40%, whereas the implementation of patients under level 2 remains limited with respectively 2% and 0,4% (table 2). Conclusion: The implementation of VBHC with a focus on personalization and systematic outcome monitoring is ongoing. Next steps will include a real world study.

14 April 2026 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
Claudia CrimiClaudia Crimi
Claudia Crimi
SOSimon Oczkowski
Simon Oczkowski
ACAnnalisa Carlucci
Annalisa Carlucci
JPJean-Louis Pépin
Jean-Louis Pépin
JHJuliane Hafermann
Juliane Hafermann
SGScott Gibson
Scott Gibson